BetterLife provides update on neuroplastogenic activity of BETR-001
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Scientific Update on BETR-001: BetterLife Pharma presented at the Bloom Burton Conference that BETR-001 is a potent neuroplastogen capable of inducing neuroplasticity, which promotes the growth of new dendrites and spines in neurons, potentially treating various psychiatric and neurological disorders.
Regulatory Progress: BETR-001 has received a composition of matter patent from the USPTO, and after completing most IND-enabling studies, the company plans to file for IND and begin human trials in the first half of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
